21st Aug 2020 09:18
(Alliance News) - Renalytix AI PLC on Friday said it will collaborate with AstraZeneca PLC on developing and launching precision medicine strategies in renal, cardiovascular, and metabolic diseases.
Shares in diagnostics company Renalytix AI were up 12% at 632.65 pence in London in morning trade. Shares in FTSE 100-listed drug maker Astra were down 0.6% at 8,500.00p.
The first stage of this collaboration will use Renalytix AI's artificial intelligence-enabled in vitro diagnostic platform KidneyIntelX to examine possible further outcome improvement for chronic kidney disease and its complications.
This stage of the collaboration will take place in coordination with the Mounta Sinai Health System with the goal of improving guideline-based standard of care in a way that optimally uses existing and novel therapies. It will use the KidneyIntelX testing platform as well as care management software.
Around 700 million patients have chronic kidney disease worldwide, a disease associated with higher risk of metabolic and haematologic complications like anaemia and hyperkalemia. Hyperkalemia is when a patient has elevated levels of potassium in their blood.
The initial stage is to assess the impact of AI-enables in vitro diagnostic solutions in optimising the use of therapeutics in chronic kidney disease with current standard of care protocols.
Based on study outcomes, a randomised controlled trial will begin evaluating uptake and adherence to new potassium-binding agents in those patients with both chronic kidney disease and hyperkalemia.
Astra and Renalytix AI are aiming to use KidneyIntelX to help improve physician uptake and patient adherence to existing potassium-binding therapeutics, as well as other chronic kidney disease products, by identifying previously hidden high-risk patient groups. They are also hoping to accelerate patient recruitment and identification for clinical trials.
Another aim in using KidneyIntelX is to complement commercialisation efforts with outcomes from KidneyIntelX results.
Barbara Murphy, dean for Clinical Integration and Population Health Management at the Icahn School of Medicine at Mount Sinai, and board member of Renalytix AI, said: "We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases, such as kidney disease, diabetes, and cardiovascular disease.
"By using a more personalised approach, our initial goal is to help realise improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System."
Tarek Rabah, vice president of AstraZeneca US Renal-Cardio, said: "This collaborative approach reflects the shared vision of AstraZeneca and Renalytix AI to develop meaningful solutions to tackle significant challenges in healthcare in a holistic way.
"We are committed to revolutionising kidney care by continuing to drive innovation. An important component of our work is identifying patients with significant unmet need and providing them with more personalised interventions."
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc